Federal investment built the platform for private health care’s expansion
American health care did not grow into a private, profit-driven industry in isolation. It expanded on top of public capital, public insurance, public research, and public regulation, with the government repeatedly creating the conditions that allowed private firms to enter, scale, and dominate. The result is an economy in which health care now accounts for more than 18% of national output, and in which many of the most lucrative activities depend on public support even when the profits themselves accrue to private actors.
The legal and policy architecture began early. The Hill-Burton Act of 1946 helped finance hospital construction and modernization after World War II, laying down physical infrastructure that private providers and vendors could then use. Medicare and Medicaid followed in 1965, creating enormous publicly financed payment streams that became central to hospital, physician, and post-acute care revenue. Decades later, the Human Genome Project and the Patient Protection and Affordable Care Act expanded the same pattern in different forms: one through federally supported scientific discovery, the other through a broader insurance and regulatory framework that increased access and commercial opportunity at the same time.
A single sentence captures the economic logic. Public policy did not merely regulate the market; it made the market possible.
Public programs, private profits, and the structure of modern medicine
This sequence matters because it reveals how deeply intertwined government action and private enterprise have become in American medicine. Hospitals, insurers, device makers, pharmaceutical companies, laboratory services, and a wide range of health technology firms all operate within systems first assembled by public money and public law. In practical terms, government spending reduces the financial risk of innovation, builds demand, and creates stable reimbursement channels. Private firms then compete to capture those streams, often by packaging care, data, or technology into proprietary products.
That arrangement has produced genuine gains. Public funding has supported hospital access, scientific discovery, expanded insurance coverage, and many of the diagnostic and therapeutic advances that now define modern practice. Patients benefit when a public program lowers the barrier to a new drug, a genome-based test, or a hospital bed in an underserved region. The public sector often absorbs the highest-risk and least profitable phase of development, while private companies step in once the path is clearer and the revenue model is established.
The same structure also creates predictable vulnerabilities. Once a private company is embedded in a publicly financed system, the incentives can shift from care delivery to extraction. Fraud, overbilling, anticompetitive conduct, and market consolidation all become easier to justify when growth is tied to reimbursement rules rather than direct patient value. In that setting, harm does not always look like a single dramatic failure. It can accumulate through inflated prices, narrower competition, reduced transparency, and organizational choices that favor margin over mission.
Health law became the system’s operating code
Because the private sector now functions inside a heavily subsidized and regulated health system, health law has become more than a specialty. It is part of the infrastructure. Payment rules, compliance obligations, fraud enforcement, antitrust oversight, privacy standards, licensing structures, research protections, and coverage mandates all shape how medical care is delivered and monetized. Without that legal scaffolding, the system would not function at its current scale.
Health lawyers therefore serve a structural role, not a peripheral one. They help institutions interpret reimbursement rules, manage regulatory exposure, structure transactions, negotiate with government payers, and respond to enforcement threats. Their work is embedded in the daily operation of hospitals, health systems, laboratories, insurers, digital health firms, and private equity-backed practices. When the sector expands or consolidates, legal work expands with it.
This is also where the public-private relationship becomes most visible. Private equity and other investment actors often move into areas already stabilized by public reimbursement or public need. Once inside, they can reorganize practices, aggregate markets, and seek returns from systems whose foundation was laid by taxpayers. Some of those transformations improve efficiency or access. Others can weaken continuity, inflate costs, or erode professional independence. The same public programs that widened access can, under certain ownership structures, become channels for financial engineering.
Fraud, consolidation, and the cost of weak guardrails
The most serious concern is not simply that private firms profit from health care. It is that some use public support to advance conduct that distorts the system itself. Fraud diverts money away from care and undermines trust in payment programs. Anticompetitive behavior can leave patients and payers with fewer choices, higher prices, and less leverage. In a sector this large, even modest distortions can have enormous downstream consequences.
The law’s job is not to eliminate private participation. That would be unrealistic and, in many domains, undesirable. Its job is to keep a publicly supported market from drifting too far from the public purposes that justified the investment in the first place. That requires active enforcement, careful transaction review, and a legal culture that treats health care not as an ordinary commodity but as a sector with distinct moral and fiscal obligations.
The article’s central claim is straightforward: government built much of the platform, and the private sector rushed in because the platform was stable, financed, and scalable. The difficult question is how to preserve the gains from that arrangement without allowing the worst incentives to dominate.
The next pressure point is governance, not invention
Future strain will likely come less from whether medicine can produce new technologies than from whether the system can govern the business structures built around them. A public program that funds hospitals, research, or insurance coverage can improve population health, but it also creates a market ripe for capture if oversight is weak. Once private actors are woven into the fabric of public care, enforcement becomes inseparable from access.
This is why the legal framework deserves as much attention as the delivery system itself. Payment policy, antitrust enforcement, fraud control, and corporate governance are not abstract back-office concerns. They determine whether publicly supported health care remains oriented toward patients or drifts toward revenue maximization. In that sense, the history of American medicine is not just a story about scientific progress or insurance expansion. It is a story about how public investment repeatedly made private growth possible, and how the law now has to manage the consequences of its own success.